Tablets of Olmetek plus are applied in essential hypertensia. The combined medicament is intended for adult patients at whom use of only one olmezartan of a medoksomil does not provide a lowering of arterial pressure to necessary level.

Structure

One tablet, coated, contains (active ingredients):

• an olmezartan - 40 mg;
• a hydrochlorothiazide - 12.5 mg.

Excipients: microcrystalline cellulose; the hydroxypropyl cellulose low-substituted; lactose, monohydrate, hydroxypropyl cellulose; magnesium stearate.

Film cover: Opadray O2A22352 or Opadray of O2A24576 containing: hydroksipropilmetiltsellyuloza 2910, talc, titan dioxide (E171), ferrous oxide yellow (E172), ferrous oxide red (E 172).

Contraindication

• hypersensitivity to active ingredients, to any of excipients or to other derivatives of streptocides (the hydrochlorothiazide also is derivative streptocides);
• heavy renal failures (clearance of creatinine <30 ml/minute);
hypopotassemia, a hypercalcemia, a hyponatremia and a clinically apparent hyperuricemia is resistant
• ;
• heavy abnormal liver functions, cholestasia and obstructive diseases of bilious ways;
• pregnancy or planning of pregnancy;
to
• combined use of medicine of Olmetek plus and medicaments containing aliskiren is contraindicated to patients with diabetes or a renal failure (SKF <60 ml/minute / 1.73 m ² ).

Tablet swallow of

entirely, washing down with enough liquid. Tablets should not be chewed. The medicament is recommended to be taken daily at the same time.

Adult

Olmetek plus is not medicament of the first choice. It is intended for patients at whom use of only one olmezartan of a medoksomil in a dose of 20 mg does not provide the necessary level of arterial blood pressure.

Pill of medicament of Olmetek plus is taken 1 time a day irrespective of meal.

in the presence of clinical indications allows the translation of the patient from monotherapy of an olmezartan medical oxolovely in a dose of 20 mg on the combined medicament at once, however at the same time it is necessary to consider the fact that the maximum hypotensive action of an olmezartan of a medoksomil is reached in 8 weeks after an initiation of treatment.

recommends titration of a dose of each of components.

.

Patients of advanced age (is more senior than 65 years)

to Patients of advanced age the combined medicament is recommended to be used in the same dose, as to adult patients.

Renal failure

in case of use of medicament of Olmetek plus to patients with renal failures easy and moderate severity (clearance of creatinine of 30-60 ml/minute) is recommended to control function of kidneys periodically. To patients with heavy renal failures (the clearance of creatinine <30 ml/minute) is contraindicated to Olmetek plus.

Abnormal liver function

to Patients with abnormal liver functions easy and moderate severity of Olmetek plus should be applied with care. To patients with abnormal liver functions of moderate severity of an olmezartan medoksomit it is recommended to apply in an initial dose 10 mg of 1 times a day, and the maximum dose should not exceed 20 mg of 1 times a day. Patients with abnormal liver functions which already accept diuretics and (or) other antihypertensive medicaments are recommended to control carefully arterial blood pressure and function of kidneys. Experience of use of an olmezartan of a medoksomil to patients with heavy abnormal liver functions is absent. To patients with heavy abnormal liver functions and also with a cholestasia and obstruction of bile ducts of Olmetek plus it is contraindicated.

Feature of use

Pregnant

Combined medicine of an olmezartan medoksomil / a hydrochlorothiazide contraindicated the pregnant women or women planning pregnancy.

is not recommended to Use medicament of Olmetek plus during feeding by a breast. At use of this medicine during feeding by a breast the dose has to be the lowest.

Safety and efficiency of use of medicine are not established to children (aged up to 18 years) by

.

Drivers

Drug of Olmetek plus can cause insignificant or moderate influence on ability to run vehicles and to work with other mechanisms. Sometimes at the patients accepting antihypertensive medicaments the dizziness and increased fatigue can be observed owing to what reaction can decrease.

Overdose

Special information concerning symptoms or treatments of overdose of medicament of Olmetek plus is absent.

For the patient carefully symptomatic supporting treatment. Symptomatic treatment also depends on time which passed from the moment of administration of drug, and from severity of symptoms. Vomitives and/or gastric lavage can be recommended. At treatment of overdose, activated carbon is sometimes recommended. It is regularly necessary to control the level of electrolytes and creatinine in blood serum. In case of arterial hypotension of the patient it is necessary to put in horizontal position and to quickly carry out intravenous infusion of isotonic solution of sodium of chloride.

Most probable manifestations of overdose of an olmezartan of a medoksomil is arterial hypotension and tachycardia, besides, there can be bradycardia. The overdose by a hydrochlorothiazide is followed by electrolytic disturbances (a hypopotassemia, a hypochloraemia) and the dehydration caused by an excessive diuresis. Frequent manifestations of overdose are nausea and drowsiness. The hypopotassemia can cause muscular spasms and/or strengthen arrhythmia, resulting from use of the accompanying medicaments (cardiac glycosides or some antiarrhytmic means).

It is removed olmezartan or a hydrochlorothiazide at a hemodialysis, it is unknown.

Side effects

Most often at use of medicament arise such side reactions as a headache (2.9%), dizziness (1.9%), increased fatigue (1.0%).

Storage conditions

does not demand special storage conditions. To store out of children's reach.

Expiration date - 5 years.